BIVI
BIOVIE INC.
NASDAQ · Healthcare · Biotechnology · US
$1.29
−25.72%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.64
From 52W high−43.64%
Volume812111.00
Market cap$11.16M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$1.64
From 52W high
−43.64%
Volume
812111.00
Market cap
$11.16M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
P/E (TTM)
—
RSI (14)
45.6
MomentumView details →
1D Return
−25.72%
YTD Return
+11.43%
SummaryUpdated Jun 1, 2026
BioVie Inc. (NASDAQ:BIVI) is a clinical-stage biotechnology company founded in 2013 and based in Carson City, Nevada. Originally incorporated as NanoAntibiotics, Inc., the company rebranded to BioVie Inc. in July 2016 and went public in September 2020. BioVie focuses on discovering, developing, and commercializing novel drug therapies, with a particular emphasis on treatments for neurological disorders and liver diseases. The company operates as a pure-play research and development organization with no current revenue-generating products, as all of its therapeutic candidates remain in various stages of clinical trials.
Similar companies
Latest newsMore news →
BioVie announced a registered direct offering to a single healthcare-focused institutional investor of 2,962,500 shares or common stock equivalents at $1.60 per share.5h agoBioVie announced that it was invited to present data on bezisterim in long COVID at the 2026 RECOVER-TLC Hybrid Workshop, scheduled for November 4–5 in Bethesda, Maryland.9d agoBioVie said its abstracts on Phase 2 trial results for bezisterim in Long COVID and Parkinson’s disease were accepted as poster presentations at the American Neurological Association’s annual meeting, scheduled for October 17–20 in San Diego.21d ago